Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world

Novartis today announced that it has entered into a development and licensing agreement with Biological E Limited (BioE), a biopharmaceutical company based in India, for two vaccines to protect against typhoid and paratyphoid fevers. The agreement advances the Novartis goal to deliver accessible and affordable vaccines that address unmet medical need in endemic regions.

Continue reading. 

As part of his role as ROTA Council co-chair, Dr. Ciro de Quadros recently wrote an opinion piece for AllAfrica.com about a new study showing that rotavirus vaccines will have a powerful public health impact in developing countries.
When we last wrote about Singapore’s dengue outbreak just over a month ago, the total number of cases had already reached over 6,000 – more than the number of cases in all of 2012. Last week, Singapore broke the 10,000 mark.

The Role of Immunization Managers

Tremendous gains have been made in immunizations over the last 40 years. Smallpox has been eradicated, poliomyelitis eradication is in sight and progress is being made in measles control. Global immunization coverage for basic vaccines is at its highest, and new vaccines are being added to immunization systems. However, challenges remain and will increase in complexity as new vaccines are added to immunization programs.

Pages

Subscribe to RSS - Vaccine Advocacy and Education